VAERS Explorer
Back to explore

Report #2899898

Received Jun 12, 2026

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Female
Age
45 yrs
State
MO
Recovered
Unknown
Vaccinated
May 18, 2026
Onset
May 18, 2026
Days to onset
0
Hospital days

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
VARZOSZOSTER (SHINGRIX)GLAXOSMITHKLINE BIOLOGICALSUNKTL74Y

Symptoms (1)

Product storage issue

Symptom narrative

Administration after below temperature excursion; 45 years old patient received Shingrix; This non-serious case was reported by a other health professional via call center representative and described the occurrence of incorrect storage of drug in a 45-year-old female patient who received Herpes zoster (Shingrix) suspension for injection in pre-filled syringe (batch number TL74Y) for prophylaxis. On 18-MAY-2026, the patient received Shingrix. On 18-MAY-2026, an unknown time after receiving Shingrix, the patient experienced inappropriate age at vaccine administration (Verbatim: 45 years old patient received Shingrix). On an unknown date, the patient experienced incorrect storage of drug (Verbatim: Administration after below temperature excursion).The outcome of the incorrect storage of drug and inappropriate age at vaccine administration were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date:04-JUN-2026 The Medical assistant reported via chat an excursion (that happened on 11-May-2026) for Boostrix, Engerix-B, Havrix, Menveo (1 vial) and Shingrix (PFS) vaccines and received the vaccines after the excursion and was asking if the patients need to be revaccinated. With a minimum temperature of 30-degree F, for 2 hours. This was 1 of 19 cases, reported by the same reporter.; Sender's Comments: US-GSK-US2026074484:SAME REPORTER US-GSK-US2026074479:SAME REPORTER US-GSK-US2026074480:SAME REPORTER US-GSK-US2026074483:SAME REPORTER US-GSK-US2026074478:SAME REPORTER US-GSK-US2026074487:SAME REPORTER US-GSK-US2026074488:SAME REPORTER US-GSK-US2026074475:SAME REPORTER US-GSK-US2026074485:SAME REPORTER US-GSK-US2026074486:SAME REPORTER US-GSK-US2026074481:SAME REPORTER US-GSK-US2026074476:SAME REPORTER US-GSK-US2026074746:SAME REPORTER US-GSK-US2026074749:SAME REPORTER US-GSK-US2026074882:SAME REPORTER US-GSK-US2026075045:SAME REPORTER